Concussion

Numinus Completes Acquisition of Neurology Centre of Toronto

Thursday, September 23, 2021 - 2:00pm

Founded in 2017 by Dr. Evan Lewis (MD), NCT will operate as the "Neurology Centre of Toronto by Numinus" and continue under Dr. Lewis' leadership.

Key Points: 
  • Founded in 2017 by Dr. Evan Lewis (MD), NCT will operate as the "Neurology Centre of Toronto by Numinus" and continue under Dr. Lewis' leadership.
  • Dr. Lewis will assume the role of VP, Psychedelic Neurology Services at Numinus.
  • The acquisition expands Numinus' presence into Ontario, in addition to an existing clinic and research facility in British Columbia, and clinics in Quebec.
  • These developments will form the basis for NCT by Numinus to expand into a clinical neurology centre with specialization in psychedelic neurology.

Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Wednesday, September 22, 2021 - 1:39pm

The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally.

Key Points: 
  • The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally.
  • Odysseys Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.
  • The most tolerated dose will be used in the subsequent trials to determine efficacy, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • Odyssey screening and enrollment of subjects coincides with the completion of their Phase 1 clinical batch of PRV-002.

Brave Care Joins Fayetteville, NC Pediatric Healthcare Community

Wednesday, September 15, 2021 - 1:00pm

Brave Care opened on Sept 13 for pediatric primary and urgent care with updated hours (open nights and weekends), on-sitepharmacy, and easy onlinebookings.

Key Points: 
  • Brave Care opened on Sept 13 for pediatric primary and urgent care with updated hours (open nights and weekends), on-sitepharmacy, and easy onlinebookings.
  • Brave Care is truly disrupting how we conduct pediatric healthcare in this country, said Dr. Corey Fish, Chief Medical Officer at Brave Care.
  • Brave Care is honored to join the Fayetteville community and to begin building relationships with the parents and children in this tight-knit community.
  • Brave Care is the modern pediatric healthcare company dedicated to improving care for kids so they can reach their full potential.

Lobe Sciences Provides Corporate Update to Investors and Stakeholders

Monday, September 13, 2021 - 2:43pm

Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:
    Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts,
    We are pleased to say that 2021 has been a busy and transformative year for the Company.
  • During 2021, we have made significant progress on several fronts, and completed our transition to an integrated pharmaceutical development company.
  • We believe that psychedelic based therapeutics will bring a new era of treatment for many illnesses where current therapies are insufficient or unavailable.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.

Odyssey Group International to Present at the HC Wainwright 23rd Annual Global Investment Conference

Thursday, September 9, 2021 - 1:00pm

IRVINE, CA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • IRVINE, CA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference.
  • Details for the presentation are as follows:
    HC Wainwright 23rd Annual Global Investment Conference:
    Following the conference, a webcast replay of the presentation will be available on the Investor section of the companys website, https://odysseygi.com/ .
  • Odyssey Group International, Inc. (OTC: ODYY ) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.
  • Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions.

SportGait Announces Partnership with North Carolina Youth Soccer Association

Tuesday, September 7, 2021 - 3:00pm

WILMINGTON, N.C., Sept. 7, 2021 /PRNewswire/ -- SportGait , a medical technology company focused on facilitating concussion diagnoses and recovery, is thrilled to announce their partnership with North Carolina Youth Soccer Association (NCYSA), today September 7, 2021.

Key Points: 
  • WILMINGTON, N.C., Sept. 7, 2021 /PRNewswire/ -- SportGait , a medical technology company focused on facilitating concussion diagnoses and recovery, is thrilled to announce their partnership with North Carolina Youth Soccer Association (NCYSA), today September 7, 2021.
  • This new partnership will provide free baseline testing for all NCYSA athletes through the end of 2021, with the ultimate goal of putting athletes' safety first.
  • "SportGait is a way for us to keep our children safe, healthy and keep our parents and coaches educated," says NCYSA Executive Director Kathy Robinson.
  • SportGait is a concussion support and recovery system that offers a scalable platform for medical providers, coaches, and parents.

Bev Wake to become next Executive Director of National Newspaper Awards

Tuesday, September 7, 2021 - 3:00pm

TORONTO, Sept. 7, 2021 /CNW/ -The Board of Governors of the National Newspaper Awards (NNAs) is pleased to announce the appointment of Bev Wake as the organization's next Executive Director, effective July 1, 2022.

Key Points: 
  • TORONTO, Sept. 7, 2021 /CNW/ -The Board of Governors of the National Newspaper Awards (NNAs) is pleased to announce the appointment of Bev Wake as the organization's next Executive Director, effective July 1, 2022.
  • To facilitate a successful transition, Wake will work closely with Woods and Program Director Sharon Hockin in all aspects of NNA operations from now until her appointment takes effect.
  • Previously she spent nearly two decades working in a variety of roles within the Postmedia newspaper chain.
  • Wake was recognized for leadership in sports media in 2017 by the Paul Carson Broadcast and Media Awards.

Alpha Cognition Reports Second Quarter of Fiscal 2021 Results

Friday, September 3, 2021 - 9:31pm

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF)(Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it has reported its Second Quarter financial results of fiscal 2021.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF)(Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it has reported its Second Quarter financial results of fiscal 2021.
  • Select Financial Information for Q2-2021:
    (for the period ended June 30, 2021)
    Research and development expenses were $1.5m for the three months ended June 30, 2021.
  • General and administrative, including Management and Professional fees, Travel, and Other G&A, were $100k for the three months ended June 30, 2021.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

Former University of South Alabama Head Women’s Volleyball Coach Sexually Harassed and Sexually, Physically and Emotionally Abused Former Players, According to New Lawsuit Filed by DiCello Levitt Gutzler

Thursday, September 2, 2021 - 9:34pm

A former NCAA Division I head womens volleyball coach sexually harassed, and physically and emotionally abused her players for several years, according to a federal lawsuit filed this week in Alabama.

Key Points: 
  • A former NCAA Division I head womens volleyball coach sexually harassed, and physically and emotionally abused her players for several years, according to a federal lawsuit filed this week in Alabama.
  • The case was brought by several former University of South Alabama volleyball players against former head coach, Alexis Meeks-Rydell.
  • Also named as defendants are the University, Athletic Director Joel Erdmann, and former assistant coaches Rob Chilcoat and Patricia Gandolfo.
  • Once on campus, however, they were routinely subjected to blatant sexual harassment and sexual, physical, and emotional assault by Meeks-Rydell.

Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board

Thursday, September 2, 2021 - 3:09pm

BALTIMORE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D.

Key Points: 
  • BALTIMORE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D.
  • A board-certified internist, Dr. Farber is the Medical Director of Executive Health at Hackensack University Medical Center and Assistant Professor of Medicine at Hackensack Meridian School of Medicine.
  • He is also the Founding Partner of Baker Street Health and Human Performance, a company that integrates health and well-being with optimal performance.
  • I am energized by this opportunity to contribute to RNADDs Advisory Board at this pivotal time.